BIOHARVEST SCIENCES INC (CNVCD)
OTC PINK OTC PINK Primary 
Bioharvest Sciences appoints new CFO
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced the appointment of Bar Dichter as its new CFO. Dichter, who has been with the company since 2018, previously served as vice-president of finance following her role as controller.
BioHarvest Sciences expects record third quarter revenue as it nears Nasdaq uplisting
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) preannounced preliminary financial results for the third quarter, noting that it expects record revenue of at least $6.5 million, marking a 100% increase from the year-ago quarter. The leader in botanical synthesis technology also guided revenue of at least $7.2 million for the fourth quarter, representing a 60% jump from Q4 2023.
BioHarvest Sciences surpasses $6M in quarterly revenue - ICYMI
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) this week released its latest quarterly financial results, a period marked by significant revenue and subscriber growth for its red grape cell nutraceutical product VINIA. CEO Ilan Sobel joined Proactive to discuss the results.
BioHarvest Sciences sees strong VINIA demand drive triple-digit revenue growth in Q2
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) saw its product revenue jump 116% year-over-year in the second quarter driven by strong sales of its flagship red grape-based nutraceutical product VINIA. Total revenues grew 119% to $6 million from $2.8 million in the year-ago quarter, marking a 13% sequential increase.
BioHarvest Sciences closes first tranche of private placement
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) told investors it has closed the first tranche of its private placement announced on June 21, 2024, raising approximately $4.3 million (approximately C$5.9 million). The leader in Botanical Synthesis said the funds raised will support its Contract Development and Manufacturing Organization (CDMO) business unit, expand manufacturing capabilities at the newly acquired 80,000-square-foot campus, and be used for general corporate purposes.
BioHarvest Sciences unveils US$5M financing
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that it will raise up to US$5 million to advance its Contract Development and Manufacturing Organization (CDMO) business unit, expand its manufacturing capabilities within the newly acquired 80,000-square-foot campus, and for general corporate purposes. The leader in Botanical Synthesis said it will issue up to 697,350 units at US$7.17 per unit for gross proceeds of up to $5 million.
